The Food and Drug Administration on Wednesday approved Novo Nordisk's new hemophilia treatment, Rebinyn.
Here are three things to know.
- Rebinyn is intended to treat adults and children with hemophilia B, an inherited blood disorder that causes prolonged or spontaneous bleeding.
- Patients may take the drug when experiencing a bleeding episode or prior to surgery so clinicians can better manage bleeding during the procedure.
- Novo Nordisk plans to release Rebinyn in the first half of 2018.
More articles on supply chain:
Amgen sues FDA over drug exclusivity rights: 5 things to know
Appellate court: Fairvew Health's medical device telemarketing does not violate robocall rules
Drug execs anticipate Trump's drug pricing plans: 4 things to know